AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
Title | AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Pentheroudakis, G., Kotoula V., Koliou G-A., Karavasilis V., Samantas E., Aravantinos G., Kalogeropoulou L., Souglakos I., Kentepozidis N., Koumakis G., Sgouros J., Zarkavelis G., Efstratiou I., Laschos K., Petraki C., Tikas I., Poulios C., Voutsina A., Goudopoulou A., Bafaloukos D., Vrettou E., Kalogera-Fountzila A., Pectasides D., & Fountzilas G. |
Journal | Clin Colorectal Cancer |
Volume | 17 |
Issue | 4 |
Pagination | e631-e637 |
Date Published | 2018 12 |
ISSN | 1938-0674 |
Keywords | Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Female, Fluorouracil, Follow-Up Studies, Humans, Irinotecan, Leucovorin, Liver Neoplasms, Male, Middle Aged, Oxaliplatin, Prognosis, Prospective Studies, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Survival Rate, Young Adult |
Abstract | BACKGROUND: The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC). |
DOI | 10.1016/j.clcc.2018.06.003 |
Alternate Journal | Clin Colorectal Cancer |
PubMed ID | 29980490 |